Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump Takes Office, Change At US FDA Arrives With ‘Beachhead Teams’

Executive Summary

Incoming president will not hold over any FDA political appointees from the Obama administration, but what exactly his stamp on the agency will be remains unclear.

You may also be interested in...



FDA's Document Dump: Guidance Release Skyrocketed In Advance Of Trump

Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.

Trump Meets With Two US FDA Commissioner Candidates; Third Still Lurking

O'Neill and Srinivasan head to Trump Tower, but Gottlieb has not been eliminated.

Trump Makes A Nasty News Day For Pharma – But What Will It Really Mean?

President-elect threatens a government bidding process to control drug pricing in his first post-election press conference.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT104344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel